New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
On December 17, 2021, Amgen and AstraZeneca announced the FDA approval of Tezspire (tezepelumab-ekko), for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.
Download PDF
Return to publications
